GILD - Gilead Sciences, Inc.
70.45 -0.10 (-0.14%)
After hours: 5:27PM EST
| Previous Close | 70.92 |
| Open | 71.36 |
| Bid | 70.13 x 800 |
| Ask | 70.97 x 800 |
| Day's Range | 70.17 - 71.71 |
| 52 Week Range | 64.27 - 89.54 |
| Volume | 4,337,944 |
| Avg. Volume | 6,675,556 |
| Market Cap | 91.265B |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | 58.55 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.28 (3.17%) |
| Ex-Dividend Date | 2018-12-13 |
| 1y Target Est | N/A |
- MarketWatch•7 hours ago
Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels
Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.
- Zacks•13 hours ago
Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges
With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.
- Reuters•2 days ago
Express Scripts offers new formulary for lower list-price drugs
Express Scripts Holding Co on Tuesday announced a new drug reimbursement list with lower U.S. prices for brand-name medications, as a way to encourage drugmakers to move away from paying rebates after a prescription is filled. The manager of prescription drug benefits for large corporate employers and government health plans said its new National Preferred Flex Formulary will be available as of Jan. 1 to all clients. Drug rebates have come under fire from the Trump Administration and consumer groups as patients find themselves paying much higher insurance co-payments and deductibles tied to a drug's sticker price.
Market Realist•3 days agoMost Analysts Are Bullish on Nektar Stock
In November 2018, of the total ten analysts covering Nektar Therapeutics (NKTR), eight analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Nektar Therapeutics stock is 1.8 with a target price of $88.5, implying an upside potential of 160.1% over Nektar Therapeutics’ trading price of $34.03 on November 10.
- MarketWatch•4 days ago
Biotech stocks have been hit hard — here are ones analysts like best for a rebound
Nine companies have majority ‘buy’ ratings, with upside potential of as much as 123%, according to analysts.
- Simply Wall St.•6 days ago
Is Gilead Sciences Inc’s (NASDAQ:GILD) Balance Sheet Strong Enough To Weather A Storm?
Gilead Sciences Inc (NASDAQ:GILD), a large-cap worth US$91.0b, comes to mind for investors seeking a strong and reliable stock investment. Market participants who are conscious of risk tend to search Read More...
- American City Business Journals•6 days ago
East Bay biotech scores $42 million with potential quick-fix for heart trouble
This company wants to make treating an irregular heartbeat as easy as reaching into your backpack, and it's just raised cash to take the first part of that vision into a mid-stage clinical trial.
- American City Business Journals•9 days ago
Exclusive: Small Peninsula city urges developer to go bigger on new housing site
After decades of anemic housing production, Belmont is luring more housing to its El Camino Real corridor including a new proposal for 250 apartments.
- Motley Fool•9 days ago
Why Gilead Sciences, Inc. Stock Broke Down in October
Investors aren't pleased with Gilead's apparent lack of direction.
Market Realist•10 days agoGilead Sciences: Analysts’ Recommendations
In November, among the 28 analysts covering Gilead Sciences (GILD), six recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold.” The mean rating for Gilead Sciences stock is 2.21 with a target price of $86.15, which implies an upside potential of 22.5% over Gilead Sciences’ closing price of $70.31 on November 1.
Market Realist•10 days agoAnalyzing Gilead Sciences’ HIV Portfolio
Gilead Sciences’ (GILD) total HIV sales got a boost from the US market. The HIV product sales in the United States increased from $2.52 billion in the third quarter of 2017 to $3.0 billion in the third quarter. The HIV product sales in Europe decreased from $656.0 million in the third quarter of 2017 to $584.0 million in the third quarter. The sales in other international markets decreased from $156.0 million in the third quarter of 2017 to $138.0 million in the third quarter. Gilead Sciences’ Biktarvy generated US sales of $375. ...
- Motley Fool•11 days ago
3 Top Biotech Stocks With P/Es Below 14
After a rough month, three top drugmakers are trading at bargain-basement prices.
- Investopedia•12 days ago
Gilead Stock to Jump Double Digits: Morgan Stanley
In a note to clients on Thursday, Morgan Stanley analysts downplayed the risk of an announcement by UnitedHealth Group Inc. ( UNH), which investors view as potentially eating into Gilead's revenues for its pricey drug treatments, as outlined by Barron's. Shares of Gilead plunged as much as 6% on Wednesday following news that UnitedHealth is launching a rewards program called My Scripts Reward, which promotes the use of low-cost therapies. Morgan Stanley analyst Matthew Harrison, who rates shares of the Foster City, Calif.-based biotechnology company at equal weight, noted a handful of issues with UnitedHealth's announcement.
- TheStreet.com•12 days ago
Gilead Sciences Is Sporting a Bearish Set of Charts for Investors
GILD has been trying to turn itself around, but few, including Jim Cramer, see that turn coming any time soon. In this daily bar chart of GILD, below, has been struggling to mount a sustained rally. Is this the start of a new downtrend or just part of a longer base-building process?
- Market Realist•12 days ago
Gilead Sciences’ Operational Performance
Gilead Sciences’ (GILD) cost of goods sold increased marginally from $1.03 billion in the third quarter of 2017 to $1.09 billion in the third quarter.
Market Realist•12 days agoWhat Does Gilead Sciences’ Bottom-Line Trend Indicate?
Gilead Sciences’ (GILD) interest expense decreased from $291.0 million in the third quarter of 2017 to $264.0 million in the third quarter. The company’s income tax provision also decreased from $959.0 million in the third quarter of 2017 to $565.0 million in the third quarter.
Market Realist•12 days agoGilead Sciences: An Update for Investors
For Gilead Sciences’ (GILD) Biktarvy, declining revenues and stock price movements have kept investors interested in the stock. In this series, we’ll explore Gilead Sciences’ financials, the performance of the company’s geographic segments, analysts’ recommendations for the stock, and the company’s valuation metrics.
- Zacks•13 days ago
bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat
bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.
- American City Business Journals•13 days ago
Decatur-based task force becoming ground zero for global elimination of hepatitis B and C
The Decatur-based Task Force for Global Health is becoming ground zero for the global elimination of hepatitis B and C.
- Zacks•13 days ago
Biotech ETFs in Focus on String of Q3 Earnings Beat
Biotech ETFs draw attention post impressive Q3 results.
Market Realist•14 days agoMerck’s Virology Segment after the Third Quarter
Merck & Co.’s (MRK) Zepatier reported revenues of $104 million in the third quarter compared to $468 million in the third quarter of 2017, reflecting a ~78% YoY (year-over-year) decline and an 8% sequential decline.
InvestorPlace•14 days ago3 Big Stock Charts for Thursday: Walmart, Prologis and Incyte
Gilead Sciences (NASDAQ:GILD) fell 5.4% after UnitedHealth Group (NYSE:UNH) unveiled a new plan that favors lower-cost HIV treatments, putting Gilead’s core business in the crosshairs. Rather, investors may want to take a closer look at Walmart (NYSE:WMT), Prologis (NYSE:PLD) and Incyte (NASDAQ:INCY). Walmart has been one of the market’s bigger winners since June, up more than 20% in that short timeframe.
- Zacks•14 days ago
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals
- MarketWatch•14 days ago
Gilead shares drop after new UnitedHealth program incentivizes cheaper HIV meds
Gilead Sciences Inc. shares dropped 6% in extremely heavy Wednesday midday trade, a move that Wall Street analysts attributed to a new program introduced by UnitedHealth Group's UnitedHealthcare division that incentivizes patients to take lower-cost HIV medications. Gilead's HIV franchise has long been a powerhouse for the company, but it has faced more sluggish sales of late. The new UnitedHealth program, My ScriptRewards, allows patients on employer-based plans and, soon, self-insured individuals cost savings and up to $500 in prepaid debit cards for medical expenses when they choose a cheaper drug regimen, with the first medications included in the program being HIV antivirals. The UnitedHealth program was first announced on Monday, notably, and Gilead shares were up this week until Wednesday. The Wednesday decline was an "overreaction," RBC Capital Markets analyst Brian Abrahams said, adding that he remains bullish on the long-term future of the company's HIV franchise. Gilead shares have dropped 13.1% over the last three months, compared with a 3.4% decline in the S&P 500 and a 0.9% decline in the Dow Jones Industrial Average .
